cyrilzakka/clinical-trials huggingface dataset:
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.


Eligibility Criteria:
Inclusion Criteria:

* Definitive diagnosis of unresectable locally advanced or metastatic RCC with clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior treatment in the metastatic setting
* Evaluable Memorial Sloan Kettering Cancer Center risk score
* Measurable disease, as defined by RECIST v1.1
* Karnofsky performance status greater than or equal to 70%
* Adequate hematologic and end-organ function prior to randomization

Exclusion Criteria:

Disease-Specific Exclusions:

* Radiotherapy for RCC within 14 days prior to treatment
* Active central nervous system disease
* Uncontrolled pleural effusion, pericardial effusion, or ascites
* Uncontrolled hypercalcemia
* Any other malignancies within 5 years except for low-risk prostate cancer or those with negligible risk of metastasis or death

General Medical Exclusions:

* Life expectancy less than 12 weeks
* Participation in another experimental drug study within 4 weeks prior to treatment
* Pregnant or lactating women
* Known hypersensitivity to any component of atezolizumab or other study medication
* History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes mellitus
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis
* Positive human immunodeficiency virus test
* Active or chronic hepatitis B or C
* Severe infections within 4 weeks prior to treatment
* Exposure to oral or IV antibiotics within 2 weeks prior to treatment
* Live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination participants must agree not to receive live, attenuated influenza vaccine within 4 weeks prior to treatment, during treatment or within 5 months following the last dose)
* Significant cardiovascular disease
* Prior allogeneic stem cell or solid organ transplantation

Exclusion Criteria Related to Medications:

* Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
* Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment

Bevacizumab- and Sunitinib-Specific Exclusions:

* History of hypertensive crisis or hypertensive encephalopathy
* Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds
Comparative Study Between Combined Vaginal Misoprostol

"Comparative study between Combined Vaginal Misoprostol with Isosorbide-5-Mononitrate

"Comparative study between Combined Vaginal Misoprostol with Isosorbide-5-Mononitrate versus Misoprostol Alone For Induction Of The first trimester Missed Abortion A Randomized Clinical Trial"

Eligibility Criteria:
Inclusion Criteria:

* - Maternal Age 18 - 35 years.
* Gestational age first trimester of pregnancy (between 5-13 weeks).
* Missed abortion confirmed by ultrasound.
* Singleton pregnancy.
* Normal uterus and cervix on clinical examination.
* Cervix is not dilated.
* No vaginal bleeding.

Exclusion Criteria:- Evidences suggesting start of spontaneous abortion and previous trial to induce abortion.

* Presence of uterine contraction or bleeding,
* Multi-fetal pregnancy.
* Suspicion of septic abortion.
* History of Previous cervical surgery or manipulation. Ex: cervical tear , cervical cauterization .
* Uterine anomaly.
* Presence of IUD( intrauterine device) in situ
* Underlying medical diseases.Ex:diabetes mellitus,hypertension
* History of allergy or adverse effects to vaginally administered medication e.g. isosorbide -5- mononitrate
* Those unwilling to participate in the trial
* Higher order cesarean section(more than three
The Effect of the Crossword Used in Nursing Education on Learning Success

The research was planned as a randomized controlled study to evaluate the effect of crossword, which are an active learning tool, on the success of learning information about pain control in nursing education. Research data is planned to be collected in Hatay Mustafa Kemal University Faculty of Health Sciences. The universe of the research will be the students who take the 3-credit pain control course in the aforementioned faculty in the fall semester. The sample of the research will consist of 72 students who meet the inclusion criteria and agree to participate in the research verbally and in writing. The data of the research will be collected by using the Personal information form prepared in line with the literature, and Success Tests (3 tests) prepared separately for each stage. SPSS program will be used in the analysis of the data.


Eligibility Criteria:
Inclusion Criteria:

* To be registered in the pain course,
* Taking the pain course for the first time,
* Absence of any psychiatric disorder that will reduce the ability to comprehend and understand,
* Agreeing to participate in the research.

Exclusion Criteria:

-Willingness to leave the research
Comparison of Intubation Conditions Between the Gliderite and the S-Guide

Intubation with an unchanneled videolaryngoscope mandates the use of a stylet. The Gliderite is a stylet specially designed for videolaryngoscopes. The investigators aim to compare the efficacy of a new designed bougie for intubation in patients with simulated difficult airways.

Intubation with an unchanneled videolaryngoscope mandates the use of a stylet. The Gliderite is a stylet specially designed for videolaryngoscopes. The investigators aim to compare the efficacy of a new designed bougie for intubation in patients with simulated difficult airways.

The primary endpoint will be time necessary for intubation, secondary endpoints will be injuries, ease of use and subjective assessment.

Eligibility Criteria:
Inclusion Criteria:

* Surgery necessitating general anesthesia and orotracheal intubation

Exclusion Criteria:

* History or criteria of difficult intubation
* Patient refusal
Bispectral Index (BIS) Values Required for an Adequate Depth of Anesthesia in Elderly Patients Using Propofol

A correlation between the bispectral index values and electroencephalographic patterns at the loss of consciousness (LOC) when using propofol in elderly patients, has not been determined.

Our aim is to describe the BIS values and the power of the alpha band in the electroencephalography in elderly patients, at the LOC moment.

Propofol is an anesthetic drug regularly used in elderly patients requiring anesthesia. The electroencephalographic pattern recognized when propofol is administered, is different to the pattern obtained in younger patients. Both groups presents an alpha and slow bands, but they differ in the intensity of the signal. Younger patients presents more intense electroencephalographic bands than older patients.

Bispectral index (BIS) is a clinical indicator used to evaluate the depth of anesthesia. A correlation between this indicator and the power of electroencephalographic bands has not been determined.

We will describe the LOC moment of elderly patients receiving propofol as anesthetic for general surgery, with the EEG characteristic bands and the BIS value obtained at that moment. The BIS values related to the EEG characteristic bands can be described, to correlate the actual indicators of depth of anesthesia with new parameters.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 65 years
* Scheduled for elective surgery requiring general anesthesia
* American Society of Anesthesiology (ASA) Score I or II

Exclusion Criteria:

* Patients with neurological diseases
* Requiring the use of two or more drugs affecting Central nervous system
* History of drugs or alcohol abuse
* Body mass index over 35 kg/m\^2
* Propofol allergy
* Cardiac congestive failure
* History of coronary syndrome
* Minimental test altered (Score under 24 points)
The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome

The purpose of this study is to determine if a low fructose intake could have an impact on weight loss, uric acid levels and the components of the metabolic syndrome (glucose, cholesterol, triglycerides, insulin resistance, high blood pressure).

Overweight and obesity are now considered a growing public health problem in Mexico and worldwide. This epidemic has been attributed to dietary fructose consumption. Although experimental models have demonstrated a role of fructose in the development of obesity, metabolic syndrome and kidney disease, data in human models is lacking. The purpose of this study is to determine if a low fructose intake could have an impact on the components of the metabolic syndrome. The primary endpoint will be to determine the impact of low fructose on weight loss. Secondary endpoints will evaluate the impact of low fructose diet on blood pressure and cardiovascular biochemical profile.

If fructose is a causal pathway to obesity and metabolic syndrome, it may represent an important target to mitigate this important health problem.

Eligibility Criteria:
Inclusion Criteria:

* Individuals with a Body Mass Index (BMI) \> 25. BMI defined as: Weight in kilograms divided by Height (squared) in meters.
* Residents of Mexico city
* Healthy individuals (no comorbidities or drug prescription for associated chronic diseases)

Exclusion Criteria:

* Diabetes Mellitus Type 1 or 2
* Severe Hypertension (defined as systolic blood pressure \> 160 mmHg and /or diastolic blood pressure \> 100 mmHg) and/or Hypertension on pharmacological treatment.
* Chronic Kidney Disease (Glomerular Filtration Rate (GFR) \< 60 ml/min)
* Hepatic Damage or Advanced Disease (clinical, biochemical or histological)
* Patient receiving any pharmacological treatments for hypercholesterolemia and/or elevated triglycerides.
* Anemia (any etiology)
* Malignancy
* Pregnancy
VIVO Mapping Protocol

This is a single centre study enrolling 15 subjects with structurally normal hearts that are already indicated for a ventricular ablation procedure (VT or PVCs).

The purpose is to compare the accuracy of VIVO and to assess its efficacy to decrease procedural time, and ideally, the procedural overall costs, as compared to standard of care ablation procedures. Results will be compared with data from

VIVO TM is a non invasive mapping system which can be used to localize PVC / VT origin prior to the ablative procedure.

Subjects scheduled for catheter ablation with VIVO will undergo a CT scan prior to the procedure, which will be used to create a personalized 3D model. This will be merged with a 3D photograph (taken at the start of the procedure) of the ECG electrodes on the subject's torso.

Then, the recording of the 12 lead ECG will be imported into the VIVO software. All of this data will be combined via the software and a mathematical algorithm will determine the origin of the arrhythmia. This will show the physician where to perform a successful ablation. After 3 months, the subject will return for follow up and will receive another ECG Holter monitor (ECG recording) to determine ablation success.

Subjects will be exited from the study after the 3 month follow up visit. Patients will receive standard clinical care prior to, during and after their scheduled procedure, as well as after being discarded from the trial.

Results will be analysed and compared to those from an historical cohort of patients (age / gender matched, undergone the same procedure) ablated by the same operator within the previous 5 years (from a database already collected). Data will be anonymised as per current regulations.

Eligibility Criteria:
Inclusion Criteria:

1. Subjects who are at least 18 years or older
2. Subjects who are scheduled for PVC/VT ablation procedure
3. Subjects who have signed an IRB/EC approved Informed Consent Form and applicable subject privacy protection authorization per local law
4. Subjects will be selected without regard to gender or age (unless precluded by local regulatory requirements)
5. Subjects with or without cardiac structural disease

Exclusion Criteria:

1. Reversible causes of PVC/VT
2. Subjects with recent (within 3 months) acute coronary syndrome
3. Subjects who are contraindicated for CT or MRI (must be able to get one)
4. Subject whose MRI or CT scan does not comply with the requirements of this protocol
5. Subjects who are contraindicated for an electrophysiology procedure and/or fluoroscopy:

   * INR \> 3.5
   * Active infection
   * Pregnancy: Females of childbearing potential with a positive pregnancy test.
6. Existing mechanical heart valve
7. Subjects with structural cardiac disease
Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

The purpose of the study is to assess the safety, efficacy and tolerability of Clobetasol propionate foam in subjects with chronic dermatitis.

The study is being conducted in order to obtain safety, efficacy and tolerability data for Clobetasol propionate foam in the treatment of chronic dermatitis. The subjects must have mild to moderate disease based on the Investigator's assessment at baseline.

Eligibility Criteria:
Inclusion Criteria:

* Subjects 18 years of age or older, with diagnosis of chronic dermatitis, able to complete the study and comply with study instructions.
* Female subjects of childbearing potential must have a negative pregnancy test. Sexually active women of childbearing potential participating in the study must have been using a medically acceptable form of contraception

Exclusion Criteria:

* Use of systemic corticosteroid and/or other prohibited medications within 4 weeks of the baseline visit.
* Use of topical corticosteroid therapy and/or other prohibited topical medications within 2 weeks prior to the baseline visit
Influence of Stress on Encoding and Prediction

The purpose of this study is to investigate the neural mechanisms by which acute stress influences statistical learning and episodic encoding.

This study aims to assess the neural and behavioral mechanisms by which acute stress modulates episodic encoding (which involves the trisynaptic pathway: entorhinal cortex, dentate gyrus, cornu ammonis \[CA\] 3, and CA 1) and statistical learning (monosynaptic pathway: entorhinal cortex, CA1) in humans.

Eligibility Criteria:
Inclusion Criteria:

* 18-45 years old
* Fluent in English
* BMI 18-35

Exclusion Criteria:

* Meeting current DSM-V criteria for any substance use disorder (except caffeine)
* Having current significant medical conditions or psychiatric symptoms requiring medication
* Current use of medications/drugs that interfere with physiological stress responses
* Peri and post-menopausal women, pregnant or lactating women, and those with hysterectomies
* Metal in body (for MRI safety) history will be assessed for female participants.
Impact of Preemptive Intravenous Ibuprofen on Postoperative Edema and Trismus in the Third Molar Teeth

this study was planned to investigate the antiinflammatory activity of preemptive intravenous ibuprofen on inflammatory complications such as edema and trismus after third molar tooth surgery


Eligibility Criteria:
Inclusion Criteria:

* Elective 3. Molar tooth extraction
* Patients between the ages of 20-35
* Patients who are symptomatic
* 3. Molar tooth angular or horizontal settled patients

Exclusion Criteria:

* Patients who refuse to participate in the study
* Patients under 20 years old, over 35 years old
* Patients who are allergic to known non-steroidal anti-inflammatory drugs
* Pregnant patients
* Patients with severe hepatic insufficiency
* Patients with severe renal insufficiency
Differential Effects of Lipids on Cardiovascular Diseases: A CALIBER Study

The role of lipids as risk factors for cardiovascular events is well-documented, although events studied have largely been broad classes without specific detail. This study will examine a more refined set of endpoints.

The role of lipids (cholesterol and triglycerides) as risk factors for cardiovascular events is well-documented. The Emerging Risk Factors Collaboration found approximately log-linear adjusted associations of cholesterol concentrations with risks of first-time non-fatal myocardial infarction; coronary heart disease (CHD) death; ischaemic, haemorrhagic and unclassified stroke. They also found that triglycerides concentration was not independently related with CHD risk after controlling for HDL cholesterol (HDL-C), non-HDL-C, and other standard risk factors. The Prospective Studies Collaboration found that Higher HDL-C and lower non-HDL-C levels were approximately independently associated with lower ischaemic heart disease mortality. By focusing on broad outcomes these large meta-analyses conflate the association between development of the different cardiovascular disease (CVD) phenotypes, disease progression and mortality from cardiovascular causes.

With linked electronic health records, we have the potential for a cohort with sufficient size and clinical detail to investigate the association between lipid concentrations and initial presentation of a range of CVD phenotypes across cerebral, coronary, abdominal and peripheral arterial circulations.

Eligibility Criteria:
Inclusion Criteria:

* Aged 30 to 100, had at least one year of electronic health record data which meet General Practice Research Database data quality standards

Exclusion Criteria:

* No record indicating any cardiovascular disease phenotypes
Treatment of Sleep Apnea With Oral Appliances

Obstructive sleep apnoea (OSA) is a serious and common disorder affecting one in twenty-five men and one in fifty women over the age of 30. This breathing abnormality occurs during sleep and is characterised by snoring and episodes of sleep disturbances. The symptoms of untreated OSA (e.g. excessive daytime sleepiness), can result in significant reductions in the patients' quality of life. The key treatment modalities today include Continuous Positive Air Pressure (CPAP), surgery and the use of oral appliances (OAs). Increasingly, OAs have been advocated in the treatment of the symptoms of OSA since they offer a non-invasive form of treatment and also because patients often prefer this treatment to other treatment modalities. There is increasing evidence to support the effectiveness of OAs in the management of OSA, at least as a short term measure. What is still unclear is which types of OA are most effective and whether OAs are effective in the long term management of OSA. This randomized clinical trial aims to evaluate two differently designed OAs in terms of their effect on patients' quality of life and on the physiological symptoms of OSA (apnoea/hypopnoea index AHI). Around 45 patients with OSA will be recruited from a pool of patients referred to the dental hospital for treatment from the medical faculty. The treatment with OAs will commence after randomization to two treatment groups; follow-up examinations will take place over a period of 12 months. The results of this study will help inform practitioners and patients of the feasibility of using OAs in the long term management of OSA and help determine the most appropriate type of OAs for the management of OSA and improvement in quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18 or older
* AHI ≥ 10-30/h, and those who do not tolerate CPAP or refused CPAP if AHI \>30
* A score of \> 10 on the Epworth Sleepiness Scale
* Body Mass Index \<35kg/m
* Those who are competent to give written informed consent
* have adequate dental anchoring structures (\<10 periodontally healthy teeth per arch)

Exclusion Criteria:

* Previous surgery to upper respiratory airway
* Concurrent unstable cardiovascular disease, neurological, mental or psychiatric disorders
* Recent major surgery in the last 6 months
* Pregnancy
* Epilepsy
* temporomandibular joint (TMJ) disfunction (pain during mandibular advancement or limitation of mouth opening)
* untreated dental decay
Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.

Constraint-Induced Movement Therapy was developed to treat stroke hemiparesis. Due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from Constraint-Induced Movement Therapy.

Eligibility Criteria:
Inclusion Criteria:

* Chronic upper extremity motor deficit due to multiple sclerosis

Exclusion Criteria:

* Relapse within 3 months of planned enrollment.
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines.

People who join this trial have tried 2 to 4 other medications to prevent their migraines, but these medications have not helped them.

When the trial is over, researchers will use this information to find out if the number of migraine days decreased more for the participants who got either dose of Lu AG09222 than for the participants who got the placebo.

Participants will be randomly allocated to one of 3 treatment groups: Lu AG09222 high dose, Lu AG09222 low dose, or placebo, in a ratio of 2:1:2.

Eligibility Criteria:
Key Inclusion Criteria:

* The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.
* The participant has a history of migraine onset at least 12 months prior to the Screening Visit.
* The participant has a migraine onset at ≤50 years of age.
* The participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications.

Key Exclusion Criteria:

* The participant has been previously dosed with an anti-pituitary adenylate cyclase-activating polypeptide (anti-PACAP) ligand-targeting antibody.
* The participant has confounding and clinically significant pain syndromes.
* The participant has a diagnosis of acute or active temporomandibular disorder.
* The participant has a history or diagnosis of confounding headaches.
Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus

Systemic Lupus (SLE) is a chronic disease for which long term treatments are warranted. The aim of this study was to study the possibility of corticosteroids interruption in patients with quiescent SLE treated since at least one year with 5 milligrams of predonisone per day.


Eligibility Criteria:
Inclusion Criteria:

* Patients with SLE according to the ACR revised criteria.
* Quiescent disease without flare since at least one year (SELENA SLEDAI \< or equal to 4, BILAG C, D or E, PGA 0) _ Treatment with 5 milligrams/day of prednisone since at least 1 year

Exclusion Criteria:

* failure to sign the informed consent or unable to consent
* Patient participating to another clinical trial
* Pregnancy or plan to become pregnant